The role of Raf kinase inhibitor protein (RKIP) in health and disease. 2004

Evan T Keller, and Zheng Fu, and Meghan Brennan
Department of Urology, University of Michigan, Ann Arbor 48109, USA. etkeller@umich.edu

Raf kinase inhibitor protein (RKIP) is a member of the phosphatidylethanolamine-binding protein (PEBP) family. RKIP plays a pivotal modulatory role in several protein kinase signaling cascades. RKIP binds inhibits Raf-1-mediated phosphorylation of MEK through binding to Raf-1. Protein kinase C (PKC) phosphorylates RKIP, resulting in release of Raf-1 and activation of MEK and ERK. The phosphorylated RKIP binds to and inhibits G-protein-coupled receptor kinase, resulting in sustained G-protein signaling. The regulatory role that RKIP has in cell signaling is reflected in its role in physiology and pathophysiology. RKIP is involved in neural development, cardiac function and spermatogenesis and appears to have serine protease activity. In addition to its roles in physiology, dysregulated RKIP expression has the potential to contribute to pathophysiological processes including Alzheimer's disease and diabetic nephropathy. RKIP has been shown to fit the criteria of being a metastasis suppressor gene, including having decreased expression in prostate cancer metastases and restoring RKIP expression in a prostate cancer cell line diminishes metastasis in a murine model. Clearly, RKIP has multiple molecular and cellular functions. In this review, RKIP's molecular roles in intracellular signaling, its physiological functions and its role in disease are described.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000727 Androgen-Binding Protein Carrier proteins produced in the Sertoli cells of the testis, secreted into the seminiferous tubules, and transported via the efferent ducts to the epididymis. They participate in the transport of androgens. Androgen-binding protein has the same amino acid sequence as SEX HORMONE-BINDING GLOBULIN. They differ by their sites of synthesis and post-translational oligosaccharide modifications. Androgen Binding Protein,Binding Protein, Androgen,Protein, Androgen Binding,Protein, Androgen-Binding
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D049488 Phosphatidylethanolamine Binding Protein A ubiquitously found basic protein that binds to phosphatidylethanolamine and NUCLEOTIDES. It is an endogenous inhibitor of RAF KINASES and may play a role in regulating SIGNAL TRANSDUCTION. Phosphatidylethanolamine-binding protein is the precursor of hippocampal cholinergic neurostimulating peptide, which is cleaved from the N-terminal region of the protein. HCNP Precursor Protein,Hippocampal Cholinergic Neurostimulating Peptide Precursor,Phosphatidylethanolamine-Binding Protein,Raf Kinase Inhibitor Protein
D019908 Proto-Oncogene Proteins c-raf A ubiquitously expressed raf kinase subclass that plays an important role in SIGNAL TRANSDUCTION. The c-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2. c-raf Proteins,Kinase Raf-1,Kinase p74(raf-1),Proto-Oncogene Protein c-raf,c-raf Kinases,cRaf1 Kinase,raf-1 Kinase,Kinase Raf 1,Kinase, cRaf1,Kinase, raf-1,Kinases, c-raf,Protein c-raf, Proto-Oncogene,Proteins c-raf, Proto-Oncogene,Proteins, c-raf,Proto Oncogene Protein c raf,Proto Oncogene Proteins c raf,Raf-1, Kinase,c raf Kinases,c raf Proteins,c-raf, Proto-Oncogene Protein,c-raf, Proto-Oncogene Proteins,raf 1 Kinase

Related Publications

Evan T Keller, and Zheng Fu, and Meghan Brennan
December 2012, Cancer metastasis reviews,
Evan T Keller, and Zheng Fu, and Meghan Brennan
October 2013, Acta histochemica,
Evan T Keller, and Zheng Fu, and Meghan Brennan
August 2004, Anti-cancer drugs,
Evan T Keller, and Zheng Fu, and Meghan Brennan
January 2014, Critical reviews in oncogenesis,
Evan T Keller, and Zheng Fu, and Meghan Brennan
February 2011, Cancer research,
Evan T Keller, and Zheng Fu, and Meghan Brennan
August 2012, Clinical & experimental metastasis,
Evan T Keller, and Zheng Fu, and Meghan Brennan
February 2022, Cells,
Evan T Keller, and Zheng Fu, and Meghan Brennan
May 2019, Cells,
Evan T Keller, and Zheng Fu, and Meghan Brennan
August 2013, Journal of cellular physiology,
Evan T Keller, and Zheng Fu, and Meghan Brennan
January 2016, Drug metabolism and disposition: the biological fate of chemicals,
Copied contents to your clipboard!